title: Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.
abstract: We studied the effect of everolimus, an inhibitor of the mammalian target of rapamycin (mTOR) on human gastric cancer cell lines. Cell proliferation in 3 of 8 cell lines was effectively inhibited by everolimus. Basal phosphorylation level of 4E-BP1 (T37/46, T70) was significantly higher in everolimus-sensitive cells than in everolimus-resistant cells. In subcutaneous xenograft model, immunohistochemistry analysis revealed that everolimus-sensitive cells expressed high levels of phospho-4E-BP1 (T37/46). In conclusion, phosphorylation of 4E-BP1 may be a predictive biomarker of everolimus sensitivity in gastric cancer.
authors: Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery (Surgery II), Nagoya 466-8550, Japan. ntetsu@med.nagoya-u.ac.jp
authors: Tetsuo
authors: T
authors: Nishi
authors: Kenta
authors: K
authors: Iwasaki
authors: Norifumi
authors: N
authors: Ohashi
authors: Chie
authors: C
authors: Tanaka
authors: Daisuke
authors: D
authors: Kobayashi
authors: Goro
authors: G
authors: Nakayama
authors: Masahiko
authors: M
authors: Koike
authors: Michitaka
authors: M
authors: Fujiwara
authors: Takaaki
authors: T
authors: Kobayashi
authors: Yasuhiro
authors: Y
authors: Kodera
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D018797:Cell Cycle Proteins; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D000068338:Everolimus; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D010750:Phosphoproteins / Q000378:metabolism*; D010766:Phosphorylation; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; C087000:EIF4EBP1 protein, human; D010750:Phosphoproteins; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus